Navigation Links
Enox Biopharma, Inc. Will Present at IN3 East Investment in Innovation Conference
Date:6/21/2011

VANCOUVER, British Columbia, June 21, 2011 /PRNewswire/ -- Enox Biopharma, Inc. CEO, John C. Rewcastle, Ph.D., will present at the IN3 East Investment in Innovation Conference on Wednesday, June 22 at 12:15 AM EST. The conference is being held at the Hyatt Regency Hotel in Boston.

The IN3 East meeting, hosted by Elsevier, is a medtech industry forum and networking meeting. The meeting is designed to provide exposure and constructive interaction between emerging medical innovation companies like Enox Biopharma and both venture capitalists and large device manufacturers.

Dr. Rewcastle will present Enox's technology whose foundation is the patent protected ability to embed nitric oxide into polymers which renders medical devices antimicrobial. He will also review recently filed intellectual property that expands Enox's technology to cover the wound healing space.

"One of the most significant problems facing the worldwide medical establishment is hospital acquired infections. In the United States alone, these infections drain an estimated $30-45 billion dollars per year. Enox is uniquely positioned to address this problem with its antimicrobial technology which utilizes nitric oxide as the mechanism of action. Nitric oxide is an ideal antimicrobial agent as it is very effective but does not have resistance issues like antibiotics do."

"The IN3 East Conference represents a great opportunity," continued Rewcastle. "Enox will be attractive to both the venture capitalists and potential strategic partners in attendance. Our breakthrough technology has the potential of meeting the needs of hospitals worldwide who are currently underserved by existing infection prevention technology. I anticipate a positive response to our presentation and presence at this event."

About Enox Biopharma, Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into polymers. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. NO is also an effective vasodilator which can lead to accelerated wound healing. Enox's device technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes and central venous catheters. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide.

For more information, please contact:

John C. Rewcastle, Ph.D, CEO or
Itamar David, CFO
Enox Biopharma, Inc.
604.637.9744 phone

888.224.7259 fax
info@enoxbiopharma.com
www.enoxbiopharma.com


'/>"/>
SOURCE Enox Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Enox Biopharma, Inc. Will Be Granted a Patent for the Delivery of Therapeutic Agents From Within Medical Devices
2. PDL BioPharma, Inc. Prices Offering of $135.0 Million of Convertible Senior Notes Due 2015
3. Plato BioPharma, Inc. Sponsors Novel Disease Model Award
4. Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference.
5. Plato BioPharma, Inc Appoints New Board Member
6. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
7. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
8. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
9. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
10. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
11. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 27, 2016 Elekta today announced ... will be the focal point of seven scientific presentations ... Society for Radiotherapy & Oncology, taking place April 29 ... state-of-the-art radiotherapy system and a high-field MRI scanner with ... the patient,s anatomy in real time. The MR-linac is ...
(Date:4/27/2016)... , April 27, 2016  Bayer Animal Health ... senior from the University of Florida College of ... Bayer Excellence in Communication Award (BECA). Brittany was ... were awarded a total of $70,000 in scholarship ... four years, Bayer has provided a total of ...
(Date:4/27/2016)... , April 27, 2016 ... USD 2.14 billion by 2022, according to a ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... affecting the efficiency and accuracy delivered by the ... demand for novel urinalysis instruments and consumables. For ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 29, 2016 , ... Regenerative Medicine Solutions (RMS) scored 94.8124 out ... earning them second place for Tampa’s Best Places to Work. They were ranked in ... a great accomplishment for our team,” says RMS Human Resources Manager Irene Miller. “We ...
(Date:4/29/2016)... San Rafael, CA (PRWEB) , ... April 29, 2016 , ... ... a week long softball camp from July 24th – 27th for girls aged 10-18. ... The camp is held at the beautiful Clark V. Whited Complex, one of the ...
(Date:4/29/2016)... ... 29, 2016 , ... HEALTHCAREfirst , the leading provider ... Deyta Analytics, recently announced the recipients of the fourth annual Hospice Honors, a ... from the caregiver’s point of view. The official list of recipients was unveiled ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec ... held May 16th to 18th at the Broward County Convention Center. The event ... to collaborate on best practices in public facility management. Intellitec Solutions will highlight ...
(Date:4/29/2016)... ... April 29, 2016 , ... Yisrayl Hawkins, Pastor and ... highlighting inconsistencies of adding BC and AD, saying it is time to set the ... After Christ. Yisrayl says this simply cannot possibly be true and offers explanation. , ...
Breaking Medicine News(10 mins):